Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Astellas Pharma Inc (OP: ALPMY )

17.08 USD -0.14 (-0.81%)
Streaming Delayed Price Updated: 3:57 PM EDT, Sep 17, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Astellas Pharma Inc

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Astellas' and Pfizer's XTANDI® (enzalutamide) Reduced Risk of Death by 34% in Men with Metastatic Hormone-Sensitive Prostate Cancer in Phase 3 ARCHES Study
Late-breaking abstract to be presented September 18 during European Society for Medical Oncology Congress 2021 
From PR Newswire
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ... 
Tags AZRX MOR NUVL
From Benzinga
Astellas' Gene Therapy Trial Hit With Another Death, FDA Slaps Clinical Hold
Astellas Pharma Inc(OTC: ALPMF) has seen thefourth death in its experimental gene therapy trialgained through a $3 ... 
Tags ALPMY Briefs News
From Benzinga
Astellas Reports Update to September 1 Announcement on the ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") reports that the ASPIRO clinical trial participant, who developed a serious adverse event as described on... 
From PR Newswire
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ... 
Tags BBI General FDA
From Benzinga
See Why Astellas Stopped Dosing In Neuromuscular Disease Gene Therapy Trial
Astellas Pharma Inc(OTC: ALPMF) hasvoluntarily paused screening and dosingof additional participants in its ASPIRO ... 
Tags ALPMY Benzinga Market News
From Benzinga
Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced that it has voluntarily paused screening and dosing of additional participants in its ASPIRO clinical... 
From PR Newswire
After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat
TheEuropean Commission (EC) has approvedFibroGen Inc(NASDAQ: FGEN) andAstellas Pharma's(OTC: ALPMF) ... 
Tags Penny Stocks ALPMF Small Cap
From Benzinga
Here's What Recent News From the FDA Means for AstraZeneca
Even though AstraZeneca and FibroGen must now conduct an additional safety trial to have a chance at FDA approval, not all is lost. 
Tags Market News FGEN ALPMY
From Motley Fool
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ... 
Tags HARP IMPL KROS
From Benzinga
Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
Roxadustat is the first orally administered hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor available for adult patients with anemia associated with chronic kidney disease in Europe 
From PR Newswire
Astellas Partners with LabCentral to Help Emerging Biotechs Accelerate Preclinical Scientific Research
Astellas' "Future Innovator Prize" sponsorship provides access to life-science incubator and in-house Astellas expertise for scientific entrepreneurs with cutting-edge ideas 
From PR Newswire
FibroGen Shares Are Trading Lower As FDA Shoots Down Roxadustat Application, Asks For Additional Trial
TheFDA has issued a complete response letterregarding the marketing application for FibroGen Inc's (NASDAQ: FGEN) ... 
Tags Anemia News Briefs
From Benzinga
Why Investors Should Like BioNTech's Latest Deal With Gilead
There are several pluses for BioNTech in the deal. 
Tags ALPMY BNTX GILD
From Motley Fool
The IPO Recap – Party Is Everything But Over
Last week's 19 IPO week had a lot of life sciences and software. This week, US IPO activity continues at a record with 25 scheduled ... 
Tags MRK ZVIA VTEX
From Benzinga
U.S. Food and Drug Administration Expands Indication for PROGRAF® for Prevention of Organ Rejection in Adult and Pediatric Lung Transplant Recipients
- PROGRAF Becomes First Immunosuppressive Drug Approved in the U.S. for People Receiving a Lung Transplant - 
From PR Newswire
Astellas - Seagen's PADCEV Wins Full FDA Approval And Expanded Label In Tough-To-Treat Urothelial Cancer
TheFDA granted full approval and a label expansionforSeagen Inc(NASDAQ: SGEN) -Astellas Pharma ... 
Tags Biotech SGEN ALPMF
From Benzinga
U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer
- Regular Approval Based on Overall Survival Results from Confirmatory EV-301 Trial - 
From PR Newswire
Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced the Committee for Medicinal... 
From PR Newswire
The 2 Best Pharma Stocks to Buy on Dips
Because the COVID-19 pandemic is under control in most major economies, the hype surrounding vaccine producers is gradually tapering off. 
Tags Healthcare Market News Stocks / Equities
From TalkMarkets
New Research Reflects Astellas' Commitment to Acute Myeloid Leukemia at EHA 2021 Virtual Congress
Eight abstracts cover FLT3 mutation-positive AML, patient treatment preferences and utilization in hard-to-treat blood cancer 
From PR Newswire
Astellas and Seagen Announce Updated Results from Two Trials of PADCEV® (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemother
- Durable Responses Observed in Second Cohort of Patients in Pivotal EV-201 Trial of PADCEV and in Initial First-Line Cohort of the EV-103 Trial Evaluating PADCEV in Combination with KEYTRUDA®... 
From PR Newswire
Astellas to Present Data from Expanding Oncology Portfolio During the 2021 ASCO Annual Meeting
Astellas' ambitious innovation and committed collaboration support new research on investigational and approved therapies in hard-to-treat cancers 
From PR Newswire
Japan's Ministry of Health, Labour and Welfare Grants Priority Review for Enfortumab Vedotin New Drug Application
NDA, submitted in March, is for locally advanced or metastatic urothelial cancer that has progressed after anti-cancer medication 
From PR Newswire
Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study Shows
Adaptimmune Therapeutics plc(NASDAQ:ADAP) hasreported first preclinical datafrom its HiT targeting mesothelin ... 
Tags ALPMY Market News Benzinga
From Benzinga
Astellas' XTANDI™ (enzalutamide) Approved by European Commission for Men with Metastatic Hormone-Sensitive Prostate Cancer
Enzalutamide is now the only oral therapy approved by the European Commission to treat three distinct types of advanced prostate cancer 
From PR Newswire
Astellas Walks Away From $450M Research & Discovery Partnership With Cytokinetics
Cytokinetics Inc(NASDAQ:CYTK)revealed in an SEC filingthatAstellas Pharma Inc(OTCMKTS: ALPMY) is ... 
Tags ALPMY Health Care Market News
From Benzinga
Astellas Takes $540M Impairment Charge Of $3B Audentes Buy­out On Gene Therapy Trial Hold
In a financial notice posted earlier today,Astellas Pharma Inc(OTCMKTS: ALPMY) said it was taking an impairment loss of ... 
Tags ALPMY FDA Market News
From Benzinga
Astellas and Seagen Announce U.S. FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
- Priority Review Granted with Action Date of August 17 - 
From PR Newswire
FibroGen Stock Is Trading Lower As CEO Admits Manipulated Safety Data For Roxadustat
FibroGen Inc(NASDAQ:FGEN) stock plummeted after hours on Tuesday after amurky disclosure for roxadustat, the ... 
Tags FGEN General Health Care
From Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.